StockNow
Calendar
Log in
U.S. Markets

Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months

StockNow breaking-news AI analysis

Bristol-Myers Squibb reported favorable Phase 3 breast cancer efficacy figures and described safety as manageable; the brief omits detailed statistical and adverse-event data.

News detail

Iza-Bren safety profile was manageable with no new safety signals identified; drug demonstrates clinical benefit in five distinct tumour types.

1 stocks
BMYBristol-Myers Squibb Co.$62.68Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

While Washington continues to exert economic pressure on Tehran, an American media report says that the US is considering a scenario of several days of attacks on Iran; a scenario that includes missile, drone, energy and nuclear facilities, ILNA reports

Geopolitics

"Missile launch by the Yemeni Armed Forces towards Saudi interests", Sabereen reports

U.S. Markets

American Express (AXP) Q3 2026 (USD): EPS 5.42 (exp. 4.50), Revenue 20.1bln (exp. 20.1bln)

AXP